Synapse

← Mathew S. Maurer

Papers by Mathew S. Maurer

Page 3 · newest first

  1. Effect of Patisiran on Stroke Volume in Hereditary Transthyretin-Mediated Amyloidosis: Insights from Pressure–Volume Analysis of the APOLLO StudyEuropean Journal of Heart Failure · 2023
  2. Analysis of lumbar spine stenosis specimens for identification of amyloidJournal of the American Geriatrics Society · 2022
  3. Clinical and genetic profile of patients enrolled in the Transthyretin Amyloidosis Outcomes Survey (THAOS): 14-year updateOrphanet Journal of Rare Diseases · 2022
  4. N‐of‐1 trials to facilitate evidence‐based deprescribing: Rationale and case studyBritish Journal of Clinical Pharmacology · 2022
  5. Sex Differences in Wild-Type Transthyretin Amyloidosis: An Analysis from the Transthyretin Amyloidosis Outcomes Survey (THAOS)Cardiology and Therapy · 2022
  6. Impact of light chain isotype on clinical features and outcomes in systemic AL amyloidosisLeukemia & lymphoma/Leukemia and lymphoma · 2022
  7. Characteristics of patients with autonomic dysfunction in the Transthyretin Amyloidosis Outcomes Survey (THAOS)Amyloid · 2022
  8. Impact of bone marrow minimal residual disease status on quality of organ response in systemic AL amyloidosisAmerican Journal of Hematology · 2022
  9. Association of Transthyretin Val122Ile Variant With Incident Heart Failure Among Black IndividualsJAMA · 2022
  10. Remote Cardiac Monitoring in Patients With Heart FailureJAMA Cardiology · 2021
  11. Clinico-histopathologic and single-nuclei RNA-sequencing insights into cardiac injury and microthrombi in critical COVID-19JCI Insight · 2021
  12. Abstract 14422: Molecular Pathogenesis of Cardiac Microthrombi in Fatal Covid-19: Insights from Clinico-histopathologic and Single Nuclei RNA Sequencing AnalysesCirculation · 2021
  13. Lack of Association Between Neurohormonal Blockade and Survival in Transthyretin Cardiac AmyloidosisSHILAP Revista de lepidopterología · 2021
  14. Can lightning strike twice? Wild-type transthyretin cardiac amyloidosis associated with rare liver diseaseOxford Medical Case Reports · 2021
  15. Temporal Trends of Wild-Type Transthyretin Amyloid Cardiomyopathy in the Transthyretin Amyloidosis Outcomes SurveyJACC CardioOncology · 2021
  16. ATTR Amyloidosis: Current and Emerging Management StrategiesJACC CardioOncology · 2021
  17. Electrophysiological Manifestations of Cardiac AmyloidosisJACC CardioOncology · 2021
  18. Phase 1a/b study of monoclonal antibody CAEL-101 (11-1F4) in patients with AL amyloidosisBlood · 2021
  19. Sex-Related Risk of Cardiac Involvement in Hereditary Transthyretin AmyloidosisJACC Heart Failure · 2021
  20. Molecular Pathophysiology of Cardiac Injury and Cardiac Microthrombi in Fatal COVID-19: Insights from Clinico-histopathologic and Single Nuclei RNA Sequencing Analyses2021
  21. Phenotypic Differences of Glu89Gln Genotype in ATTR Amyloidosis From Endemic Loci: Update From THAOSCardiology and Therapy · 2021
  22. Prefrailty, impairment in physical function, and risk of incident heart failure among older adultsJournal of the American Geriatrics Society · 2021
  23. Screening for ATTR amyloidosis in the clinic: overlapping disorders, misdiagnosis, and multiorgan awarenessHeart Failure Reviews · 2021
  24. Efficacy of Tafamidis in Patients With Hereditary and Wild-Type Transthyretin Amyloid CardiomyopathyJACC Heart Failure · 2020
  25. Frailty subtypes and recovery in older survivors of acute respiratory failure: a pilot studyThorax · 2020
  26. Impact of Tafamidis on Health-Related Quality of Life in Patients With Transthyretin Amyloid Cardiomyopathy (from the Tafamidis in Transthyretin Cardiomyopathy Clinical Trial)The American Journal of Cardiology · 2020
  27. Admission Cardiac Diagnostic Testing with Electrocardiography and Troponin Measurement Prognosticates Increased 30‐Day Mortality in COVID‐19Journal of the American Heart Association · 2020
  28. Long-term integrated safety of patisiran in patients with hereditary transthyretin-mediated amyloidosis with polyneuropathyEuropean Heart Journal · 2020
  29. Comparing outcomes for infiltrative and restrictive cardiomyopathies under the new heart transplant allocation systemClinical Transplantation · 2020
  30. Diuretic Dose and NYHA Functional Class Are Independent Predictors of Mortality in Patients With Transthyretin Cardiac AmyloidosisJACC CardioOncology · 2020
  31. Anticoagulation with warfarin compared to novel oral anticoagulants for atrial fibrillation in adults with transthyretin cardiac amyloidosis: comparison of thromboembolic events and major bleedingAmyloid · 2020
  32. Unveiling outcomes in coexisting severe aortic stenosis and transthyretin cardiac amyloidosisEuropean Journal of Heart Failure · 2020
  33. Outcomes after heart transplantation for al compared to ATTR cardiac amyloidosisClinical Transplantation · 2020
  34. Cardiac Amyloidosis: Evolving Diagnosis and Management: A Scientific Statement From the American Heart AssociationCirculation · 2020
  35. DISCOVERY: prevalence of transthyretin ( TTR ) mutations in a US-centric patient population suspected of having cardiac amyloidosisAmyloid · 2020
  36. Daratumumab plus CyBorD for patients with newly diagnosed AL amyloidosis: safety run-in results of ANDROMEDABlood · 2020
  37. Older Adults Can Successfully Monitor Symptoms Using an Inclusively Designed Mobile ApplicationJournal of the American Geriatrics Society · 2020
  38. Untangling the physiology of transthyretin cardiac amyloidosis by leveraging echocardiographically derived pressure–volume indicesEuropean Heart Journal · 2020
  39. Phase 3 Multicenter Study of Revusiran in Patients with Hereditary Transthyretin-Mediated (hATTR) Amyloidosis with Cardiomyopathy (ENDEAVOUR)Cardiovascular Drugs and Therapy · 2020
  40. Cardiac Amyloidosis: Overlooked, Underappreciated, and TreatableAnnual Review of Medicine · 2020
  41. Markers of nutritional status and inflammation in transthyretin cardiac amyloidosis: association with outcomes and the clinical phenotypeAmyloid · 2019
  42. The quintessential form of diastolic heart failure in older adults: Wild type transthyretin cardiac amyloidosisClinical Cardiology · 2019
  43. Expert Consensus Recommendations for the Suspicion and Diagnosis of Transthyretin Cardiac AmyloidosisCirculation Heart Failure · 2019
  44. Chronotropic incompetence and autonomic dysfunction as mechanisms of dyspnoea in patients with late stage cardiac amyloidosisAmyloid · 2019
  45. One year follow up analysis of the phase 1a/b study of chimeric fibril-reactive monoclonal antibody 11-1F4 in patients with AL amyloidosisAmyloid · 2019
  46. Transthyretin cardiac amyloidosis in continental Western Europe: an insight through the Transthyretin Amyloidosis Outcomes Survey (THAOS)European Heart Journal · 2019
  47. Facilitated Peer Mentorship to Support Aging Research: A RE‐AIM Evaluation of the CoMPAdRE ProgramJournal of the American Geriatrics Society · 2019
  48. Effects of Patisiran, an RNA Interference Therapeutic, on Cardiac Parameters in Patients With Hereditary Transthyretin-Mediated AmyloidosisCirculation · 2019
  49. Meta‐Analysis Global Group in Chronic (MAGGIC) Heart Failure Risk Score: Validation of a Simple Tool for the Prediction of Morbidity and Mortality in Heart Failure With Preserved Ejection FractionJournal of the American Heart Association · 2018
  50. Home-Delivered Meals Postdischarge From Heart Failure HospitalizationCirculation Heart Failure · 2018